SCHEMBL29876641

SCHEMBL29876641

CON(C)C(=O)c1ccccc1NC(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.49
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
IDO1 P14902 1/20 0.41
METAP1 P53582 1/20 0.41
KMT2A Q03164 3/20 0.40
BRD9 Q9H8M2 1/20 0.40
CYP1A2 P05177 2/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTT P42858 1/20 0.39
HPGD P15428 1/20 0.39
JAK3 P52333 1/20 0.39
BTK Q06187 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7385007 1.00 RXFP1 (0.49) RXFP1LMNAPOLBIDO1METAP1
SCHEMBL15919261 0.82 NAMPT (0.41) RXFP1IDO1METAP1RAB9AATR
SCHEMBL9330701 0.81 KMT2A (0.61) RXFP1LMNAPOLBKMT2ACYP1A2
SCHEMBL7387494 0.81 MASP2 (0.46) POLBKMT2AKDM4EALDH1A1CYP2C19
SCHEMBL29702265 0.79 RXFP1 (0.55) RXFP1LMNAPOLBKMT2ABRD9
SCHEMBL222446 0.79 RXFP1 (0.55) RXFP1LMNAPOLBKMT2ABRD9
SCHEMBL15368377 0.79 RXFP1 (0.59) RXFP1LMNAPOLBIDO1METAP1
SCHEMBL29663621 0.79 RXFP1 (0.55) RXFP1LMNAPOLBIDO1KMT2A
SCHEMBL29992092 0.79 RXFP1 (0.59) RXFP1LMNAPOLBIDO1METAP1
SCHEMBL17047340 0.79 MEN1 (0.44) RXFP1KMT2AMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022203267-A1 DUAL ANTAGONIST FOR ADENOSINE A2A RECEPTOR AND ADENOSINE A2B RECEPTOR AND USE THEREOF 주식회사 스탠다임 2022-09-29 WO disclosed